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Background: The bacterium Burkholderia mallei is the etiological agent of glanders, a highly contagious, often fatal
zoonotic infectious disease that is also a biodefense concern. Clinical laboratory assays that analyze blood or other
biological fluids are the highest priority because these specimens can be collected with minimal risk to the patient.
However, progress in developing sensitive assays for monitoring B. mallei infection is hampered by a shortage of useful
biomarkers.
Results: Reasoning that there should be a strong correlation between the proteomes of infected tissues and circulating
serum, we employed imaging mass spectrometry (IMS) of thin-sectioned tissues from Chlorocebus aethiops (African green)
monkeys infected with B. mallei to localize host and pathogen proteins that were associated with abscesses. Using
laser-capture microdissection of specific regions identified by IMS and histology within the tissue sections, a more
extensive proteomic analysis was performed by a technique that combined the physical separation capabilities of liquid
chromatography (LC) with the sensitive mass analysis capabilities of mass spectrometry (LC-MS/MS). By examining
standard formalin-fixed, paraffin-embedded tissue sections, this strategy resulted in the identification of several proteins
that were associated with lung and skin abscesses, including the host protein calprotectin and the pathogen protein
GroEL. Elevated levels of calprotectin detected by ELISA and antibody responses to GroEL, measured by a microarray of
the bacterial proteome, were subsequently detected in the sera of C. aethiops, Macaca mulatta, and Macaca fascicularis
primates infected with B. mallei.
Conclusions: Our results demonstrate that a combination of multidimensional MS analysis of traditional histology
specimens with high-content protein microarrays can be used to discover lead pairs of host-pathogen biomarkers of
infection that are identifiable in biological fluids.
Keywords: Imaging mass spectrometry, Biomarker, Burkholderia mallei, Burkholderia pseudomallei, Laser capture
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Elevated levels of pathogen-specific antibodies and anti-
gens are indicators of current or recent infection, while
perturbations of other serum proteins can illuminate dis-
ease progression and recovery. The identification of
these classes of critical biomarkers in biological fluids
obtainable by non-invasive means is generally performed by
trial and error. Thus, progress in diagnosis and treatment of* Correspondence: rulrich@bhsai.org
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unless otherwise stated.many infectious diseases will greatly benefit from higher
throughput methods for the discovery of biomarkers associ-
ated with immune responses to infection. Burkholderia
mallei is a gram-negative bacterium that causes glanders
[1], a disease primarily affecting Equidae, most commonly
horses, which may transmit to humans by direct contact
with infected animals [2]. Although human infections are
rare, B. mallei can enter the body through the eyes, nose,
mouth, or breaks in the skin [3]. Contact with the skin may
lead to a localized infection, while inhalation of aerosolized
B. mallei can lead to acute or chronic infections that have a
mortality rate greater than 50% even when treated withThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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public health concern for potential human infection from
acts of bioterrorism. There are no vaccines for glanders,
few reliable diagnostic tests and little information concern-
ing correlates of immunity. Glanders is diagnosed in the la-
boratory by isolating B. mallei from blood, sputum, urine
or skin lesions. Limited use of PCR based tests [6], comple-
ment fixation and agglutination assays [7] were also
reported.
Mass spectrometry based on matrix-assisted laser de-
sorption ionization (MALDI) utilizes a reactive matrix
that is co-crystalized with analytes to enhance ionization
induced by UV laser activation energy for measurement
of ion masses by time of flight (TOF). MALDI imaging
mass spectrometry (IMS) is a specific approach that is
used to map the spatial distribution of analytes in tissue
sections at a level of detail that is not possible by other
methods [8]. To perform IMS, tissue sections are coated
with matrix on conductive slides, and analyzed by
MALDI TOF-TOF. Spectra are collected in MS reflector
mode by a defined laser raster pattern, with each laser
pulse generating a single image pixel. An ion intensity
map is used to visualize the relative abundance and
spatial distribution of analytes in situ. Digital overlays of
MS spectral maps with standard histology images can
then be used to co-localize proteomic data within tissue
features observable by microscopy. Despite many tech-
nical obstacles that need to be overcome in this develop-
ing field [9], IMS has been successfully used to study the
tissue distribution of lipids [10], proteins [11], peptides
[12], and pharmaceuticals [13]. Contrary to other im-
aging techniques, such as immunohistochemistry (IHC)
and fluorescent microscopy, IMS does not require any
target or tissue specific reagents and is capable of simul-
taneously analyzing hundreds of molecular features [14].
Tissue specimens are most commonly fixed with formalin
and embedded in paraffin (FFPE) for microscopic analysis.
Formalin-fixation preserves tissue structure by cross-
linking proteins and also serves to inactivate infectious
agents. Unfortunately, this standard method of tissue
preparation is detrimental to IMS due to the difficulty in
obtaining tryptic digests of formalin cross-linked proteins
that provide interpretable MS2 fragmentation data [15].
Formalin fixation can be partially reversed [16] by heating
the tissue to temperatures up to 100°C, thus making it
possible to use FFPE tissue for IMS. However, there are
few reported IMS studies that have used FFPE tissue proc-
essed for antigen retrieval, and thus the limitations of this
approach are not clear. We used IMS to examine FFPE tis-
sues from Chlorocebus aethiops monkeys infected with B.
mallei. The objective was to identify the specific pathogen
and host-response biomarkers within FFPE tissues that
were also detectable in serum. Utilizing antigens identified
through tissue analysis with IMS, we also examined serumantibody responses by a focused proteome microarray
comprised of Burkholderia proteins. Our study demon-
strates that IMS can be used to recover proteomics data
from formalin-fixed tissue and that these results can be
used to identify serum biomarkers of infection.
Results
Imaging mass spectrometry
An overview of the experimental process that was used to
link proteomic data from infected tissues to biomarkers
detectable in serum is shown in Figure 1. Lung and skin
tissues procured during necropsy of Chlorocebus aethiops
monkeys that succumbed to aerosol infection by B. mallei,
as well as non-infected controls, were examined for in-
flammation and bacterial burden associated with glanders.
Evidence of the targeted bacteria within processed tissues
(FFPE) was obtained from microscopic observation of
H&E (Figure 2A) and anti-Burkholderia IHC stained slides
(Figure 2B). Because the respiratory tract was the primary
route of infection, we first examined lung tissue that
contained an abscess with B. mallei observable by IHC
(Figure 2B). Microscopic analysis of the H&E section
showed an abscess composed of cellular debris, numerous
degenerate neutrophils, and macrophages that contained
abundant intracytoplasmic basophilic material composed
of rod shaped bacteria. The area immediately surrounding
the abscess consisted of numerous macrophages, small
blood vessels, elongated fibroblasts, and collagen.
A 5 μm tissue section that was adjacent to the infected
specimen identified by histology was processed for
MALDI-IMS. The IMS results revealed 12 potential ions
that were localized to the areas known to contain B.
mallei and had an increased signal compared to the con-
trol background (Figure 2C). All of these ions were in-
creased within the central abscess and some were also
elevated in the secondary abscess (Figure 2B,C). To build
a database of potential ions from B. mallei, a bacterial
whole cell lysate was digested and analyzed by LC-MS/
MS. This analysis resulted in the generation of a B. mal-
lei specific library containing nearly 500 proteins and
more than 1300 unique peptides. Peptides from the
most abundant proteins were compared to the masses
presented in Figure 2C. This strategy resulted in a ten-
tative match to the peptide YVASGMNPMDLK from
GroEL, with a mass of 1325.6 m/z. The mass spectrum
from a spot within the abscess clearly shows the presence
of a 1325.6 m/z analyte compared to the background
(Figure 2D).
Laser capture microdissection and LC-MS/MS analysis
Because the bacterial proteins within the histology slides
were likely to be only a small fraction of the total protein
present in the tissue section, we used laser capture mi-
crodissection (Figure 3) to isolate material associated
Figure 1 Overview of the proteomics strategy for biomarker discovery. Abscesses of infection were microscopically identified in thin-sectioned
tissues (formalin-fixed, embedded in paraffin) by histology (H&E stained) and localization of bacteria by specific antibody (IHC). The tissue sections were
next examined by imaging mass spectrometry (IMS) to identify analyte masses that were localized to the selected regions of interest. Using
laser-capture microdissection of select regions of the tissue sections identified by IMS and histology, a more extensive proteomic analysis could then
be performed by a technique that combines the physical separation capabilities of liquid chromatography (LC) with the sensitive mass analysis
capabilities of mass spectrometry (LC-MS/MS). Finally, the LC-MS/MS data was compared to masses observed by IMS for highest confidence in
biomarker identification.
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surrounding host tissue. Pooled microdissections from five
serial sections were examined by LC-MS/MS (Figure 4),
resulting in the identification of several peptides from
GroEL (Figure 4A), including the peptide sequence
YVASGMNPMDLK observed in the whole cell lysate
(Figure 4B,C). Although the peptide was a tentative se-
quence match with the sequence from the B. mallei whole
cell lysate, the MS1 mass (1356.6 m/z) was not identical
due to oxidation of the methionine residues. To determine
if methionine oxidation was an artifact of tissue prepar-
ation and analysis by LC-MS/MS, recombinant GroEL
was tryptically digested for analysis by MALDI TOF TOF.
Our results with the recombinant GroEL revealed the pep-
tide YVASGMNPMDLK with no methionine oxidation
and a MS1 mass of 1325.6 m/z (Figure 5). Taken together,
this data indicated that the ion mass of 1325.6 detected by
IMS within infected lung tissue was indeed a peptide
fragment from B. mallei GroEL. In addition to GroEL
from B. mallei, 480 other host proteins (Additional file 1:
Table S1) were identified in the abscess. To maximize
identification of potential host proteins, the MS2 spectra
were searched against the curated Swiss-prot database for
Cercopithecidae (Old World monkeys).Associations between serum and tissue markers
Microsections of infected skin from another Chlorocebus
aethiops monkey (not the same subject from which the
lung biopsy was obtained) was examined to confirm that
the GroEL peptide was more than just a tissue-specific
marker. For both lung and skin tissue, the 1325.6 m/z
analyte co-localized with B. mallei in the IMS and IHC
image overlay shown in Figure 6. These results sug-
gested that GroEL was present at a distal site of infec-
tion as well as the primary portal of entry. As there is no
experimentally determined 3-dimensional structure for
the B. mallei protein, the GroEL tertiary structure was
predicted (100% confidence) using Phyre2 [17], based
upon the published crystal structure of GroEL from E.
coli with a 76% sequence identity [18]. The peptide se-
quence YVASGMNPMDLK is located between two adja-
cent alpha helixes on the protein surface (data not
shown), and is likely to be readily accessible to trypsin.
Because our objective was also to identify pathogen bio-
markers within FFPE tissues that were associated with
host serological responses to infection, we also examined
antibody response to GroEL. A microarray comprised of
approximately 300 recombinant proteins from B. mallei,
including GroEL as well as control proteins from the
Figure 2 Histopathology and imaging of B. mallei infection in the lung of a Chlorocebus aethiops monkey. Tissues were collected at the
time of death. (A) Histological image (H&E stain) of infected lung tissue. (B) Immunohistochemistry using B. mallei-specific antibody to visualize
bacteria. (C) Collection of ion intensity maps, spatial resolution of 75 μm, localized to site of infection. Signal intensity images are presented as a
blue (lowest) to red (highest). (D) Mass spectrum extracted from the inflammatory abscess (R1-Blue) overlaid with the mass spectrum from two
background regions (R2-Red and R3-Green) normalized to total ion current. The ion 1325.6 m/z is more abundant in the abscess compared to
the background.
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ure serological immune responses to infection. The re-
combinant proteins were printed in 120 μm microarray
spots on slides coated with a thin layer of nitrocellulose,
and antibody interactions with the immobilized antigens
were measured (Figure 7A) using previously described
methods [19,20]. We observed that Chlorocebus aethiops
monkeys infected with B. mallei exhibited a 10–100 fold
increase in antibodies specific to GroEL compared to anti-
body responses against the control proteins y1030 and
y1025 from Y. pestis (Figure 7B).
To delineate the qualitative host protein changes we
compared host protein abundances in the lesion (posi-
tive IHC stain) to a control area in the same tissue
(negative IHC stain). This comparison resulted in the
detection of 35 host protein changes in the lung and
125 host protein changes in the skin (Figure 7C). To
strengthen the confidence in host protein changes, onlyproteins identified in both the skin and lung lesion were
considered. This analysis resulted in 15 proteins (Table 1)
that were qualitatively different when compared to the re-
spective controls (Figure 7B). We selected calprotectin for
more detailed analysis because of a previously reported as-
sociation with other gram-negative infections [11]. Sera
were obtained from three nonhuman primates species
(Chlorocebus aethiops, Macaca mulatta, and Macaca fas-
cicularis) infected with B. mallei, and calprotectin levels
were measured by ELISA. Calprotectin was significantly
elevated in sera from all infected individuals compared to
noninfected controls (Table 2). Our results indicated that
elevated levels of the host protein calprotectin within in-
fected skin and lung correlated with increased serum
levels and that this biomarker of infection was detectable
in three primate species. We noted that bacteremia oc-
curred in only two of the six infected Chlorocebus
aethiops, while five individuals later succumbed to
Figure 3 Laser-capture tissue microdissection. (A) Diseased lung tissue was formalin-fixed, embedded in paraffin and stained with Mayer’s
hematoxylin. (B) Microscopic image (2X magnification) indicating the region prior to microdissection (green circle). (C) Microdissected target area
of the tissue section captured on an adhesive cap. (D) Tissue section showing the removed microdissected area.
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a better indicator of active infection.
Discussion
We used MALDI IMS combined with optical micros-
copy to examine proteomic changes in tissues from
Chlorocebus aethiops monkeys infected with B. mallei,
and to identify correlations between biomarkers from
solid tissue and serum. Abundant protein-derived ions
were observed in lung and skin tissues of subjects in-
fected by aerosol exposure to the virulent bacterial
pathogen. By coupling MALDI IMS, laser capture mi-
crodissection, and LC-MS/MS we were able to identify
bacterial GroEL as a specific biomarker of B. mallei
infection. Two-dimensional intensity distributions of
detectable analytes indicated that GroEL was only asso-
ciated with solid tissue sites harboring bacteria. Protein
microarray analysis enabled us to observe robust anti-
body responses to GroEL in all infected Chlorocebus
aethiops monkeys, allowing us to connect a pathogen
marker detectable in tissue with host responses readily
detected in serum. In addition, qualitative analysis of
host proteomic changes revealed perturbations in pro-
tein compositions of the infected lesions that were con-
sistent with inflammation and active immune responses.
In particular, we further examined calprotectin and
found that levels were significantly elevated within the
serum as well as infected solid tissues of infected pri-
mates. Calprotectin is a cytosolic protein of neutrophils
and is a clinical marker for intestinal inflammation [21].Although we only examined calprotectin in detail, it is
possible that other host proteins within the skin and
lung abscesses were also elevated in serum as a result of
B. mallei infection and may be equally important disease
biomarkers. Thus, standard FFPE tissue sections proc-
essed for optical microscopy were used as primary
sources of proteomic data to facilitate the identification
of the pathogen protein GroEL and the host response
protein calprotectin as paired markers of B. mallei infec-
tion. Taken together, our results indicate that IMS can
be used for discovery of biomarkers that are relevant to
infectious diseases. Although tissues from an animal
model of glanders were used for our study, it is also con-
ceivable that human biopsy material could be used as a
starting point for biomarker discovery by the method we
describe.
Considering the abundance, safety and availability of
FFPE tissue, the utility of combining MALDI IMS with
LC-MS/MS samples enriched by laser capture microdis-
section of histology specimens is an important advance-
ment for biomarker discovery demonstrated by our
study. Presently, the dynamic range of MALDI IMS and
the ability to process FFPE tissue are significant limiting
factors [14]. Formalin-fixation induces diverse chemical
modifications of peptides, including the formation of
methylol groups, Schiff bases, and methylene bridges
[15]. Tyrosine, arginine, and lysine residues are most re-
active, although other amino acid side chains are also
susceptible to formalin modification, which is also highly
dependent on protein tertiary structure [22]. The GroEL
Figure 4 Identification of the bacterial protein GroEL from infected Chlorocebus aethiops lung tissue. (A) Total protein coverage attained for
GroEL from LC-MS/MS data generated from the LCM tryptic digestion. The peptide sequence YVASGMNPMDLK is boxed in red. (B) CID MSMS spectra of
1356.6, which matched GroEL peptide YVASGMNPMDLK, with a mass deviation of −1.8 ppm. (C) Fragment b and y ions that matched predicted b and y
ions are highlighted in blue and red, respectively. Graphed below is the observed mass deviation from predicted mass for each matched fragment ion.
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likely to be solvent accessible, while the most reactive
side chains (tyrosine and lysine) are buried within two
separate alpha helices [17]. Since formalin treatment oc-
curs prior to heating or any other tissue manipulation, it
is possible that the GroEL tyrosine and lysine side chainswere buried and not freely available for chemical modifi-
cation in the tissues examined. However, we obtained
proteolytic fragments of GroEL from infected tissues
that were treated with a heat-induced antigen retrieval
process prior to trypsinization. Alternative chemical or
enzymatic approaches may be useful to obtain peptides
Figure 5 Recombinant B. mallei GroEL analyzed by MALDI TOF-TOF. (A) Total protein coverage of GroEL was 46 percent. YVASGMNPMDLK
was observed by MALDI MSMS without methionine oxidation. (B and C) CID MSMS spectra of YVASGMNPMDLK with a mass of 1325.6 m/z.
Fragment b and y ions that matched predicted b and y ions are highlighted in blue and red respectively.
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a subject area that should be systematically examined in
future studies.
We considered the significance of our initial observations
on identifying biomarkers of B. mallei infection. GroEL is a
very abundant and conserved protein of gram-negative
bacteria that was previously reported to be highly immuno-
genic in human and non-human primates [23]. In addition
to its potential use as a diagnostic, GroEL is being explored
for use in vaccines against tuberculosis, brucellosis, and
yersiniosis bacterial infections [24-26]. Further, GroEL
may be expressed on the outer cellular membrane of the
closely related B. pseudomallei, and is actively secreted by
Bartonella bacilliformis [27,28]. The peptide sequence we
detected by MS is specific to the genus Burkholderia, and
thus may have utility in distinguishing between infections
caused by Burkholderia spp. and related gram-negative path-
ogens, for example Pseudomonas aeruginosa and Klebsiella
pneumoniae. Discriminating B. mallei infections from those
caused by the very closely related human pathogen B. pseu-
domallei will require inclusion of additional species-specific
biomarkers. For the case of infections caused by strains of B.
pseudomallei, which exhibit substantial genetic variabilityand contrasting pathologies, a more extensive analysis of
additional tissues will be required before the final utility of
the specific markers we describe can be determined. For ex-
ample, a recent genetic analysis by Sarovich and coworkers
identified a B. mallei-like actin polymerization bimA(Bm)
gene that was strongly linked to neurological disease and a
filamentous hemaglutinin gene, fhaB3, that was associated
with positive blood cultures but negatively correlated with lo-
calized skin lesions without sepsis [29]. The results we
present, though targeted specifically to glanders, illustrate a
general approach for discovery of biomarkers that are rele-
vant to other infectious diseases.
Conclusions
We used imaging MS coupled with laser capture microdis-
section and LC-MS/MS to identify disease-associated pro-
teins that were present in FFPE tissues from African green
monkeys infected by aerosol exposure to B. mallei. Lead
pairs of host-pathogen biomarkers of infection that were
identified in tissues by the combined MS methods were also
readily observed in biological fluids from infected subjects.
Our results demonstrate that there can be a strong correl-
ation between proteins associated with infections of solid
Figure 6 Histopathology comparison of the 1325.6 IMS in both diseased lung (A) and skin (B) from individual Chlorocebus aethiops
monkeys. Digital microscopic images obtained from immunohistochemical identification of B. mallei in diseased lung and skin sections were
overlaid with IMS images for ion 1325.6. Digital images of healthy control tissue sections of lung and skin were used as negative controls.
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strates the utility of combining a multidimensional mass
spectrometric analysis of traditional histology specimens
with high content protein microarrays for discovery of bio-
markers that are relevant to infectious diseases.
Materials and methods
Ethics statement
All animal research was conducted under a protocol
(AP-12-022) approved by the Institutional Animal
Care and Use Committee (IACUC) at USAMRIID, in
compliance with the Animal Welfare Act, PHS Policy,
and other Federal statutes and regulations relating to
animals and experiments involving animals. The facility
where this research was conducted is accredited by the As-
sociation for Assessment and Accreditation of Laboratory
Animal Care, International and adheres to principles stated
in the Guide for the Care and Use of Laboratory Animals,
National Research Council, 2011. All animal housing areas
were continuously monitored for temperature and humidity
using a state-of-the-art monitoring system; results were dis-
played and assessed regularly to ensure animal health andwelfare. The USAMRIID Veterinary Medicine Division pro-
vided quality animal care, including housing, feeding, and
environmental enrichment, for all animals 24 hours a day, 7
days a week for the duration of the study, in accordance
with the recommendations of the Weatherall report, “The
use of non-human primates in research”. The staff included
American College of Laboratory Animal Medicine boarded
veterinarians who are experts in the field of laboratory ani-
mal care and use. All animals were examined and evaluated
twice per day by trained study personnel. Early endpoint
criteria, as specified by the score parameters within the
“Post-exposure observations” section of the approved
protocol, were used to determine when animals should be
humanely euthanized to ameliorate any suffering.
Tissue preparation
All animal research was conducted under an IACUC ap-
proved protocol in compliance with the Animal Welfare
Act, PHS Policy, and other Federal statutes and regulations
relating to animals and experiments involving animals. The
facility where this research was conducted is accredited by
the Association for Assessment and Accreditation of
Table 1 Relative abundance of specific host proteins from infected lung and skin tissues
Diseased fold-change1
Description General function Accession Lung Skin
Calprotectin Innate immunity F6QJD8 +255 +
78 kDa glucose-regulated protein Adaptive immunity F7C3R1 +14 +
Alpha-1-acid glycoprotein 1 Acute phase protein G7PRL2 + +10
Alpha-1-antichymotrypsin Acute phase protein F6SL79 + +8
C3 and PZP-like alpha-2- macroglobulin domain-containing protein 1 Inflammation induced G7PYU9 +20 +256
Calreticulin (CRP55) Calcium homeostasis F7FMQ2 +67 +
Endoplasmin Immune chaperone F7EZT6 +10 +256
Erythrocyte band 7 integral membrane protein isoform a Red blood cell protein F7HP19 +255 +
Fibrinogen alpha chain Clotting F6UZ60 +25 +203
Hemoglobin alpha chain Red blood cell protein G7Q017 −20 +12
Hemoglobin subunit beta Red blood cell protein F7APQ4 +3 +
Leukocyte elastase inhibitor Innate immunity G7P4B6 +27 +
Purine nucleoside phosphorylase (Fragment) Purine metabolism G8F5P6 +10 +
Scinderin Secretory pathway F6T8Z7 + +
Serum amyloid A protein Acute phase protein F7DY68 +63 +4
Superoxide dismutase [Mn] mitochondrial Innate immunity Q8HXP2 +75 +26
1Label-free quantitative analysis of proteins analyzed by LC-MS/MS. Data labeled with only a “+” symbol denotes proteins that were detected in the infected
animals but not in the uninfected control under these experimental conditions.
Figure 7 Differentially detected host and pathogen proteins of B. mallei infection. (A) Heatmap of IgG interactions from Chlorocebus
aethiops sera (individuals in columns) with microarrayed B. mallei proteins (in rows). (B) Antibody responses (±SD) to GroEL in comparison to
controls were significantly elevated (p≤ 0.05) in serum collected after infection with B. mallei (middle panel) from four Chlorocebus aethiops
monkeys that succumbed to infection, on days 5 (ID 1), 11 (ID 2), 13 (ID 3), 14 (ID 4); and in serum collected on 28 from one monkey that
recovered from infection (ID 5). There were no measurable antibody responses from any of the monkeys to the control proteins y1030 and y1025
from the closely related bacterium Yersinia pestis (lower panel). (C) Venn diagram representing the number of qualitative host protein changes
observed in the lung (35), the skin (125), and overlapping (15). The proteins overlapping in the Venn diagram are presented in Table 1.
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1 5 1.45 >12.5*
2 11 1.09 >12.5*
3 13 0.70 >12.5*
4 14 1.89 7.27*







1 28 2.8 >25
2 28 3.2 16.8*
3 28 1.9 23.3*
4 28 1.5 21.9*







1 28 8.3 17.8
2 28 1.0 9.0*
3 28 1.5 6.4*
4 28 2.1 7.2*
1Calprotectin concentration determined by ELISA, averaging the absorbance
(450nm) of at least two technical replicates per primate and comparison to a
standard curve.
2This was the only individual of this species surviving infection by aerosol
exposure to B. mallei.
*: p ≤ 0.05.
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ciples stated in the Guide for the Care and Use of Labora-
tory Animals, National Research Council, 2011. All non-
human primate studies were performed in BSL3 contain-
ment suites at the United States Army Medical Research
Institute of Infectious Diseases. Animals were exposed to a
targeted inhalation dose of 3 × 107 colony forming units of
B. mallei (strain FMH23344). Lung and skin tissue samples
from Chlorocebus aethiops (African green monkeys) were
soaked in a 10% neutral buffered formalin solution for 21
days and sera were γ-irradiated prior to removal from the
BSL3 suite. FFPE tissue was partitioned in 5 μm-thick sec-
tions using a Leica RM2255 microtome (Leica Microsys-
tems, Buffalo Grove, IL) and deposited onto an indium tin
oxide-coated conductive glass slide (Delta Technologies
Ltm, Loveland, CO). Samples for IMS were prepared from
a modified protocol as previously described [16]. Briefly,
paraffin wax was removed with two 100% xylene washes (5
minutes) and the tissue was gradually hydrated in succes-
sive graded ethanol washes (100% twice, 95%, and 70% for
3 minutes each). Finally the tissue was washed twice in
HPLC grade water (3 minutes each). Antigen retrieval was
performed in a decloaking chamber (BioCare Medical LLC,
Concord, CA) by heating the slides to 105°C for 20 minutes
in 10mM Tris HCl pH 7.5, under 5 psi pressure. The slides
were allowed to cool to <55°Cthen removed from the decloaking chamber, gently rinsed
with HPLC grade water, and allowed to dry (20°C).
Histology and immunohistochemistry
Adjacent tissue sections for each tissue were stained with
hematoxylin and eosin for general histology. For immuno-
histochemistry, polyclonal antibodies for B. mallei were
generated in-house. Briefly, rabbits were immunized with
400 μg of formalin-killed whole cell B. mallei. Two
booster immunizations of 400 μg were given 1 month and
4 months after the primary immunization. Rabbits were
bled 2 years after the initial immunization and the anti-
body containing serum was isolated. FFPE tissue sections
were placed on superfrost plus slides (Thermo), deparaffi-
nized, rehydrated, blocked with methanol hydrogen perox-
ide for 30 minutes, and rinsed in phosphate-buffered
saline (PBS), pH 7.4, for immunohistochemistry. Serum-
free CAS-Block (Life Technologies, Grand Island, NY)
containing 5% goat serum (Vector Labs, Burlingame, CA)
was applied to the slide for 30 minutes. The polyclonal B.
mallei antibody was diluted 1:500 in PBS and incubated
with the tissue (60 min, 20°C). After washing, polymer la-
beled horseradish peroxidase anti-rabbit secondary anti-
body (Dako, Carpinteria, CA) was applied for 30 minutes,
rinsed, counter stained with hematoxylin, dehydrated, and
cover-slipped with Permount (Thermo, Hampton, NH).
Whole slide images were scanned for analysis and ma-
nipulation using an Aperio Scanscope CS (Leica Biosys-
tems) to assess lesions.
On-tissue digestion and matrix application
Trypsin (40 μg) was dissolved in 500 μL of (5% acetonitrile,
10mM ammonium bicarbonate pH 8.0) to achieve a final
concentration of 80 ng/μL. The diluted trypsin solution was
automatically sprayed onto processed tissue sections with an
ImagePrep sprayer (Bruker, Billerica, MA) using the default
trypsin application method until all 500 μL was deposited
onto the slide (approximately 45 minutes). The slide was
allowed to dry completely between trypsin deposition itera-
tions. The slide was placed into a petri dish with moistened
blotting paper to maintain humidity, and incubated for 12
hrs (37°C). After digestion, a 1:10 dilution of calibration solu-
tion #1 (Applied Biosystems, Grand Island, NY) was mixed
1:1 with α-cyano-4-hydroxycinnamic acid [CHCA] (7 mg/
mL in 50% acetonitrile/0.5% TFA) and 0.4 μL was spotted
around the four corners of the tissue and allowed to dry. Fi-
nally, CHCA was sprayed over the slide using the automatic
TM-Sprayer (HTX Technologies, Carrboro, NC) as de-
scribed previously [30].
Imaging mass spectrometry
IMS experiments were performed using an AB Sciex 5800
MALDI TOF-TOF (Applied Biosystems), with an Nd:YAG
laser operating at 349 nm and a fixed laser beam diameter of
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a microscope slide adaptor to be used with the stainless steel
carriage (LaserBio Labs, Sophia-Antipolis Cedex, France). To
bridge conductivity between the slide and the carriage, cop-
per tape (Electron Microscope Sciences, Hatfield, PA) was
used to fix the slides to the MALDI plate. Prior to im-
aging, a plate map and internal calibration were per-
formed using Calmix1 (Applied Biosystems). For data
acquisition, 4800 imaging software (Applied Biosys-
tems) was used to automatically raster the laser in 75
μm in both the X and Y directions. MS1 analysis was
performed in reflector positive mode, scanning 500–
2500 m/z with a focus mass of 1250 m/z. For each
‘pixel’, 50 laser shots were fired at 1000Hz.
Imaging data analysis
Disk image files (.img) recorded by the 4800 Imaging
Software were opened for analysis in TissueView V1.1
(Applied Biosystems). Mass spectrometry images were
extracted and normalized to total ion current (TIC). The
IMS spectra were digitally superimposed on IHC imaged
slides by using Adobe Photoshop CS3 (Adobe Systems
Incorporated, San Jose, CA).
Laser capture microdissection
The FFPE sections were fixed onto 1.0 PEN membrane
slides (Zeiss, Jena, Germany) and stained with Mayer’s
hematoxylin to aid in visualization, as described previ-
ously [31]. Regions of interest containing bacteria or re-
gions free from infection were identified and targeted for
dissections by the Arcturus laser capture microdissec-
tion system (Life Technologies). Dissected tissue was
captured on Adhesive Caps (Zeiss) for further process-
ing. One spot from the region of interest was cut from
five adjacent tissue sections and pooled for analysis. The
micro-dissected tissue was fragmented with trypsin,
using a LiquidTissue digestion kit (Expression Pathology,
Rockville, MD) according to the manufacturer’s
directions.
Protein digestion in solution
A lysate from purified and irradiated B. mallei was prepared
as described previously [32]. Peptides from recombinant
GroEL from B. mallei (Uniprot ID#: Q9F712) were produced
as previously described [31]. Both recombinant GroEL and
B. mallei whole cell lysate were subjected to tryptic digestion
in-solution according to the manufacturer’s instructions
(Thermo). Briefly, 10 μL of a 1 μg/μL protein solution was
mixed with 15 μL of 50mM ammonium bicarbonate pH 8.0
containing 50 mM dithiothreitol, and heated to 95°C for 5
minutes. The samples were cooled (20°C), 3 μL of a 100mM
iodoacetamide solution was added and incubated 20 minutes
(20°C) in the dark. Finally, 1 μL of a 100ng/μL trypsin solu-
tion (50 mM ammonium bicarbonate, pH 8.0) was addedand incubated for 12 h (30°C). The tryptic peptides were
desalted by passing over C18 spin columns, according to the
manufacturer’s protocol (Thermo).
LC MS/MS mass spectrometry analysis
Unless otherwise noted all peptides were analyzed by LC-
MS/MS on a Thermo Fisher Orbitrap ELITE (Thermo).
On line liquid chromatography was performed on a Dio-
nex Ultimate 3000 RSLnano pump (Thermo). Peptides
were separated (35°C) on a 15 cm × 75 μm ID HPLC col-
umn packed with 3 μm C18 particles 100Å (Thermo),
using a 135 minute gradient of 5-90% acetonitrile with
0.1% formic acid. Orbitrap MS1 scans were performed at a
resolution of 120,000, with a scan range of 350–2000 m/z,
and 20 MS2 data-dependent spectra were simultaneously
acquired in the low resolution linear ion trap (top 20
method). The minimum signal required to trigger a data
dependent scan was 5000. Collision induced dissociation
(CID) was used to generate MS2 spectra with the follow-
ing settings: normalize collision energy 35, activation Q
0.25, and activation time 20ms. A lock mass of 445.120030
was used to improve mass accuracy.
In-solution digestion mass spectrometry: B. mallei whole
cell digest/peptide library
Peptides generated from B. mallei whole cell lysate were
analyzed using the Orbitrap and were searched against a
FASTA file specific for Burkholderia (Tax ID: 32008) using
SEQUEST HT in Proteome Discoverer 1.4. Variable modifi-
cations were set for carbamidomethylation, +57.02 Da;
N-terminal acetylation, +42.01 Da; oxidation of methio-
nine, +15.99 Da; and phosphorylation of STY, +79.97 Da.
Minimum peptide length was specified to 6 amino acids
and the maximum number of missed cleavages set to two.
The minimal MS1 mass tolerance was set to 10 ppm and
the fragment mass tolerance was set to 0.6 Da. A false dis-
covery rate was calculated using PERCOLATOR and was
set at <1% to score high-confidence peptide identifications,
and significant protein identification was based on inclusion
of two or more high-confidence peptide identifications.
Laser capture microdissection mass spectrometry: global
host protein identification
Peptides from generated from LCM were analyzed by LC-
MS/MS on a Thermo Fisher Orbitrap ELITE (Thermo).
Data generated from the orbitrap was searched against a
FASTA file specific for the Old World Monkey proteome
(Cercopithecidae: Tax ID 9567) using SEQUEST HT in
Proteome Discoverer 1.4. Variable modifications were set
for carbamidomethylation, +57.02 Da; N-terminal acetyl-
ation, +42.01 Da; oxidation of methionine, +15.99 Da; and
phosphorylation of STY, +79.97 Da. Minimum peptide
length was specified to 6 amino acids and the maximum
number of missed cleavages set to two. The minimal MS1
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tolerance was set to 0.6 Da. A false discovery rate was cal-
culated using PERCOLATOR and was set at <1% to score
high-confidence peptide identifications, and significant
protein identification was based on inclusion of two or
more high-confidence peptide identifications.
B. mallei identification using PEAKS
Peptides from generated from LCM were analyzed by LC-
MS/MS on a Thermo Fisher Orbitrap ELITE (Thermo). To
maximize potential identifications generated from the orbi-
trap (.raw files), data was processed and analyzed by using
PEAKS 7.0 (Bioinformatics Solutions Inc., Waterloo,
Canada) due to its proprietary method that involves both
de novo sequencing and database searching against the
swissprot/reviewed FASTA file for Burkholderia [tax ID:
32008]. Variable modifications were set for carbamidometh-
ylation, +57.02 Da; N-terminal acetylation, +42.01 Da; oxi-
dation of methionine, +15.99 Da; and phosphorylation of
STY, +79.97 Da. Minimum peptide length was specified to
6 amino acids and the maximum number of missed cleav-
ages set to two. The minimal MS1 mass tolerance was set
to 10 ppm and the fragment mass tolerance was set to 0.6
Da. A false discovery rate of <1% was used to score high-
confidence peptide identifications from a database search
and a de novo identification must have an ALC% >80 to be
considered for analysis.
Recombinant GroEL analyzed by MALDI TOF TOF
Peptides from recombinant GroEL from B. mallei (Uni-
prot ID#: Q9F712) were analyzed on an AB Sciex 5800
MALDI TOF-TOF in MSMS reflector positive mode.
Prior to MSMS analysis a survey MS1 scan was first taken.
Peaks from the survey scan were interpreted so that
MSMS data was acquired on the strongest precursors first
(up to 20). This methodology was used for three different
interpretation ranges: 900–1500, 1500–2000, and 2000–
3500 m/z. A survey peak with a signal to noise less than
35 was ignored. The MSMS spectra were collected by
firing 1000 laser shots at 1000Hz. MS2 collision energy
was set to 1kV and collision induced dissociation was
used with atmospheric air as the collision gas. The MSMS
data files were exported from Data Explorer (Applied
Biosystems) as .t2d files and processed using MASCOT
distiller (Matrix Science, Boston, MA) into MGF files, then
searched against a FASTA file specific to the Burkholderia
mallei proteome [tax ID: 320389], using SEQUEST HT in
Proteome Discoverer 1.4 (Thermo Fisher). Variable modi-
fications were set for carbamidomethylation, +57.021 Da;
N-terminal acetylation, +42.011 Da; oxidation of methio-
nine, +15.995 Da; and phosphorylation of Ser, Thr or
Tyr, +79.966 Da. Minimum peptide length was specified
to 6 amino acids and the maximum number of missed
cleavages set to two. The minimal MS1 mass tolerancewas set to 50 ppm and the fragment mass tolerance was set
to 0.6 Da. Only peptides corresponding to GroEL/Q9F712
with Xcorr values >2.0 for +1 charge state were considered
for analysis.
Label free quantitation of host proteins
A region that stained negative for the presence of B. mallei
and the diseased abscess were isolated and pooled using
LCM. Peptides generated from these regions were ana-
lyzed by LC-MS/MS on a Thermo Fisher Orbitrap ELITE
(Thermo) in triplicate. To quantitatively compare host
protein changes in the two regions, the triplicate runs
were grouped and the data were processed and analyzed by
using PEAKS 7.0 (Bioinformatics Solutions Inc., Waterloo,
Canada) against the swissprot/reviewed FASTA file for the
Old World Monkey proteome (Cercopithecidae: Tax ID
9567). Variable modifications were set for carbamidometh-
ylation, +57.02 Da; N-terminal acetylation, +42.01 Da; oxi-
dation of methionine, +15.99 Da; and phosphorylation of
STY, +79.97 Da. Minimum peptide length was specified to
6 amino acids and the maximum number of missed cleav-
ages set to two. The minimal MS1 mass tolerance was set
to 10 ppm and the fragment mass tolerance was set to 0.6
Da. A false discovery rate of <1% was used to score high-
confidence peptide identifications from a database search
and a de novo identification must have an ALC% >80 to be
considered for analysis. For quantitation all runs were first
normalized to total ion current. A protein was considered
quantitatively different if it met the following conditions:
1) more than one peptide was identified from it, 2) the
protein must be detectable in all three technical replicates
(triplicate runs), and 3) the fold change must be greater
+/− 2.0. Label-free quantitation was performed by peak
area integration normalized to total ion current for
each peptide identified. Proteins were considered to be
significantly different between samples based on a −10 log
P score of 20 (equivalent to a p value of 0.01).
Recombinant protein microarray
Host antibody responses to GroEL were examined in a
microarray format (manuscript in preparation). The micro-
array consisted of >300 recombinant Burkholderia proteins
and controls. The protein targets selected for this microarray
were essential enzymes, virulence factors, and vaccine candi-
dates. The proteins were produced in an E. coli expression
system and affinity purified using tags present in the
recombinant proteins. Briefly, genes encoding the Burkhol-
deria proteins, including GroEL, and control proteins from
Yersinia pestis (hupB, y1030; bolA, y1025) were cloned into
pEXP7-DEST, a glutathione-S-transferase, T7-based E. coli
expression vector (Life Technologies). Soluble proteins were
affinity purified using GSTrap HP columns on an FPLC
chromatography system (GE Healthcare Life Sciences, Pis-
cataway, NJ). The purified proteins were characterized for
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nalyzer 2100 (Agilent Technologies, Santa Clara, CA). The
protein microarray was produced by spotting purified re-
combinant proteins (0.1 mg/ml) in 4 replicates on
nitrocellulose-coated slides (Maine Manufacturing, Sanford,
ME), using an inkjet printer (Arrayjet North America, Cam-
bridge, MA). The printed spots were approximately 120 μm
in diameter. The microarray was probed with sera from the
B. mallei infected animals. The slides were first blocked with
a blocking buffer (PBS, 0.1% Tween-20, and 3% BSA). Sera
were diluted 1:150 (PBS containing 3% BSA and 0.2%
Tween 20) and incubated on the microarray surface. Anti-
body binding was detected by adding anti-human IgG-
Alexafluor 647 (1:1000) conjugate (Life Technologies). The
slides were dried and scanned by GenePix 4000B laser scan-
ner (Molecular Devices, Sunnyvale, CA), and image analysis
was performed using GenePix Pro 6.0 software.Calprotectin ELISA
The abundance of calprotectin in the serum was examined
using a commercially available Calprotectin (Serum) ELISA
kit from DRG International, Inc. (Springfield, NJ, USA). The
assay was performed according to the manufacturer’s proto-
col. Serum samples were diluted 1:50 (Chlorocebus aethiops
only) or 1:100 (all others) with wash buffer prior to analysis.
Quantitation of calprotectin within the serum samples was
calculated by generating a standard curve with recombinant
human calprotectin that was provided in the kit. A 4-
parameter-algorithm was used to fit the data generated from
the standard curve [Concentration (semi-log) vs. Absorbance
at 450nm] and calculate unknown concentrations from raw
absorbance values. A two-tailed Student’s T test was used
to determine statistical significance, using p ≤ 0.05 as the
acceptance criterion.Additional file
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